EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, BTAI: Bioxcel Therapeutics Inc

05 Nov 25 15:59
LAST:

1.860

CHANGE:
 0.00		OPEN:
1.860		HIGH:
1.930		ASK:
0.000		VOLUME:
582.2K
CHG(%):
0.00		PREV:
1.860		LOW:
1.830		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 251.8601.9301.8301.860582.2K
04 Nov 251.8802.0001.8401.860611.2K
03 Nov 252.0002.0001.9001.900590.5K
31 Oct 252.0402.0701.9762.050556.6K
30 Oct 252.0802.1471.9802.020834.7K
29 Oct 252.1802.1802.0502.070892.1K
28 Oct 252.2802.2882.1502.180752.8K
27 Oct 252.3402.4002.2602.280748.1K
24 Oct 252.2802.4572.2472.330784.0K
23 Oct 252.2002.2802.1402.260647.8K

COMPANY PROFILE

Name:Bioxcel Therapeutics Inc
About:BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Sector:Healthcare
Industry:Biotechnology
Address:555 Long Wharf Drive, New Haven, CT, United States, 06511
Website:https://www.bioxceltherapeutics.com
CUSIP:09075P105
CIK:0001720893
ISIN:US09075P2048
FIGI:BBG00K20GVD2

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.944.2%
MA10:2.0811.9%
MA20:2.2822.4%
MA50:2.7949.8%
MA100:2.8050.8%
MA200:2.2822.5%
RSI14:17.39 
WPR14:-100.00 
MTM14:-0.45
ROC14:-0.19 
ATR:0.15 
Week High:2.1817.2%
Week Low:1.831.6%
Month High:2.8754.3%
Month Low:1.8322.5%
Year High:8.08334.4%
Year Low:0.161,062.5%
Volatility:42.12 

RECENT SPLITS

Date Ratio
10 Feb 20251-16